Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVF injection in the temporomandibular joint for TMJ disorders
NL-OMON45520Withdrawn
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of autologous adipose stromal vascular fraction in temporomandibular disorder (TMD) and Temporomandibular Osteoarthritis (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: Pain during movement at 26 weeks and Pain at rest at 26 weeks. Planned start Apr 2017; status: withdrawn.
02
Drugs
autologous adipose stromal vascular fraction
03
Conditions
temporomandibular disorder (TMD)Temporomandibular Osteoarthritis
Beyond the preview
Go deeper on NL-OMON45520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45520.